Thursday, January 12, 2012
Actos Linked To Deadly Cancer In Lawsuit
Friday, January 6, 2012
Actos Bladder Cancer Lawsuits Filed Nationwide
Patients who have used the medication Actos in order to hopefully treat and prevent complications of their diabetes have sometimes fallen victim to a number of side effects associated with the drug, one of the most serious being bladder cancer. A number of plaintiffs such as Shirley DiGiacomo have already filed their Actos lawsuits, trying to gain restitution after discovering they suffer from conditions as severe as certain kinds of cancer. The drug maker, Takeda Pharmaceuticals North America, must soon be ready to face a growing number of lawsuits that deal with alleged side effects, a number of them severe.
DiGiacomo's lawyer alleges that his client not only suffers from bladder cancer, but that her bladder cancer is related to the diabetes drug Actos. This case is not unlike a number of Actos bladder cancer lawsuits that have already been filed; most of the claims are criticizing Takeda Pharmaceuticals and alleging that they are guilty of both negligence and breach of warranty when it comes to Actos, a product that some argue is causing more harm than good. The most dire concern is that Takeda failed to effectively warn the public of the potential for possible Actos side effects and as a result, a number of patients were not properly informed of all the potential for risks when they agreed to use the product.
Monday, November 21, 2011
Actos Lawsuits surge in Illinois
More actos
lawsuit are being filed by people who claim the type 2 diabetes drug caused
them to develop bladder cancer. The most recent actos bladder cancer
lawsuit, filed in federal court in Illinois by a Georgia woman, Josephine
Stodgill, alleges Takeda Pharmaceuticals failed to warn patients about the
bladder cancer risk associated with Actos.The Stodgill lawsuit is just the
latest to be filed by a victim of bladder cancer allegedly caused by Actos. So
far, at least 54 cases have been filed in federal district courts throughout
the U.S. plaintiffs argue that Takeda failed to properly research the
medication or warn about the risk.
Recent research has suggested that actos
side effects may increase the risk of bladder cancer the longer the
medications is taken. Actos is expected to be named in hundreds of lawsuits
claiming it caused users to develop bladder cancer.
Actos Risks Post Potential Threats at Same Rate as Avandia
Actos (pioglitazone)
was approved by FDA to treat Type 2 Diabetes in July, 1999. It is Takeda
Pharmaceuticals’ best-selling drug, with sales of $3.4 billion last year. Sales
have increased in recent years since a number of studies have suggested that Actos side effects appeared safer than its competitor, Avandia,
which has been linked to an increased risk of heart attacks and deaths. Some
experts and even federal regulators have called for an Avandia recall,
which would likely lead to even greater use of Actos to treat diabetes,
possibly increasing the risk of Actos bladder cancer sufferers. In 2005 results from the PROactive
Study (PROspectivePioglitAzone Clinical Trial in Macro Vascular Events)
demonstrated a higher percentage of bladder cancer cases with Actos
use than in competitors’ drugs following three years of research leading
victims to file an Actos lawsuit. That information was not included when
the study’s findings were published.
Sunday, November 20, 2011
Bladder Cancer Risks WithActos May Be Found In Other Diabetes Drugs
A class action actos lawsuit has been filed against
Takeda Pharmaceuticals and Eli Lilly on behalf of all users of the diabetes
drug Actos, seeking financial compensation and medical monitoring as a result
of the drug makers’ failure to adequately warn about the risk of bladder
cancer from Actos. But Actos is not the only drug to contain its active
chemical, pioglitazone. Avandia and Actos are members of a drug family called
the thiazolidinediones, abbreviated TZDs. This is a relatively new class of
oral anti-diabetic drugs which was developed during the 1990s. These drugs
began their careers showing great promise in the treatment of insulin
resistance, and hopes were raised by preliminary research that they might be
able to rescue failing beta cells.Unfortunately, over time all three were found
to cause life-threatening actos
side effects, the risk of which was far greater than the benefit these
drugs provided.
The potential risk of actos bladder cancer
problems is now being reviewed by health regulators in the United States
and other countries throughout the world.
Rate of Bladder Cancer WithActos Leads To Mounting Lawsuits
On June 15, 2011, the U.S. Food and Drug Administration (FDA) released a ‘Drug Safety Communication,’ informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of actos bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. In a five-year interim analysis of the Kaiser Permanente Northern California, study, the FDA found that there was no significant increase in the risk for bladder cancer in patients taking pioglitazone. However, it was found that the risk for bladder cancer did grow with increasing dose and use longer than one year. The data showed that pioglitazone treatment for over 12 months carried a 40% increased risk of bladder cancer.
In recent months, dozens of individuals throughout the United States have filed a bladder cancer actos lawsuits, alleging that Takeda pharmaceuticals failed to adequately research their medication or warn about the potential risks associated with use and knowingly sold the drug while being aware of those risks. Plaintiffs indicate that they are bringing the Actos class action to recover money damages, medical monitoring and other relief for all individuals who ingested Actos are having Actos Side effects in the United States or its territories since it was introduced in July 1999.
Friday, November 18, 2011
Consolidation of Actos Lawsuits Into MDL Requested
Actos is the best-selling type II diabetes drug in the world,
but over the summer, growing concerns about its possible link to actos bladder cancer reached a crescendo. On June 15, 2011, the U.S. Food & Drug
Administration (FDA) issued a safety communication stating that use of Actos for
more than one year may be associated with an increased risk of bladder cancer.
That same month, sales of the drug were suspended in France and Germany after a
separate study commissioned by French regulators demonstrated an increased risk
of bladder cancer associated with actos side effects in people who took it the longest and at the highest
cumulative dose. On July 12, Takeda Pharmaceuticals officially recalled Actos
from the market in France.
If an Actos MDL is formed, all cases
involving allegations that plaintiffs developed bladder cancer from Actos would
be transferred to the same judge. In addition, as actos lawyer continue
to review and file new complaints in federal courts throughout the United
States, those cases would also be transferred into the MDL for pretrial
litigation.Actos (pioglitazone) was approved by the FDA
to treat Type 2 Diabetes in July, 1999.
Subscribe to:
Posts (Atom)
